By Bhanvi Satija LONDON, Feb 2 (Reuters) - French drugmaker Sanofi said on Monday that its experimental genetic disorder ...

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

Regeneron (REGN) stock in focus as the company posts Q4 2025 beat as its revenue tied to Sanofi (SNY) partnership offsets headwinds to Eylea franchise. Read more here.

LONDON, Jan 29 (Reuters) - French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit ...

Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of ...

This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global ...

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of ...

Sanofi (SNY) shares traded slightly lower in Paris on Thursday even as the French drugmaker reported higher-than-expected ...

Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...

Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 ...

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from ...